AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12215691
Drug: Immediate post-surgical
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate post-surgical intravenous ketoprofen (Group II)
Trial: 2576216
Drug: 0.10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 mg/kg vecuronium
Trial: 2576216
Drug: 0.20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20 mg/kg vecuronium
Trial: 30095728
Drug: Bedtime administration
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime administration of aspirin (100 mg)
Trial: 30095728
Drug: Daytime administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daytime administration of aspirin (100 mg)
Trial: 25678774
Drug: Oxycodone once-a-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone once-a-day controlled-release (CR) tablets (20 mg)
Trial: 25678774
Drug: Commercial products
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial products (10 mg bis in die [bid])
Trial: 24188685
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg twice daily plus modified FOLFOX-6
Trial: 24188685
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg twice daily plus FOLFIRI
Trial: 24188685
Drug: Bevacizumab 5
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 5 mg/kg every 2 weeks plus modified FOLFOX-6
Trial: 24188685
Drug: Bevacizumab 5
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 5 mg/kg every 2 weeks plus FOLFIRI
Trial: 21615341
Drug: Spinal bupivacaine
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal bupivacaine 10 mg (Group 1)
Trial: 21615341
Drug: Ropivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 10 mg (Group 2)
Trial: 21615341
Drug: Ropivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 10 mg with sufentanil 2.5 mcg (Group 3)
Trial: 21615341
Drug: Ropivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 10 mg with sufentanil 5 mcg (Group 4)
Trial: 11426071
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (zidovudine/didanosine/nevirapine)
Trial: 8960733
Drug: Tablet levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet levodopa/carbidopa (LD/CD)
Trial: 3620048
Drug: Full-dose (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose (0.5 ml) intramuscular injection of PVRV on days 0, 3, 7, 14 and 28
Trial: 3620048
Drug: 2-site intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Trial: 3620048
Drug: 4-site intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Trial: 3620048
Drug: 1-site intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Trial: 29203380
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection (PI)
Trial: 27411763
Drug: Cognitive-behavioral therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy-based program for reducing internalized stigma, provided for 8 weeks (12 sessions)
Trial: 22228560
Drug: SterolQ₁₀ (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SterolQ₁₀ (100 mg single dose)
Trial: 22228560
Drug: generic CoQ₁₀
FDA approved: no
EMA approved: no
PMDA approved: no
Description: generic CoQ₁₀ (100 mg single dose)
Trial: 22228560
Drug: SterolQ₁₀ (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SterolQ₁₀ (100 mg/day for 4 weeks)
Trial: 22228560
Drug: generic CoQ₁₀
FDA approved: no
EMA approved: no
PMDA approved: no
Description: generic CoQ₁₀ (100 mg/day for 4 weeks)
Trial: 20238367
Drug: Crestal approach
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crestal approach to lift the sinus lining with 8 mm implants
Trial: 21594216
Drug: 5 mm
RxNorm normalized name: SUR-FIT 45 mm Wafer, Small
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mm short implants
Trial: 10320178
Drug: Topical lidocaine-prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine-prilocaine cream (EMLA) applied transdermally for 3 hours before CT removal
Trial: 10320178
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine administered 0.5 hours before CT removal
Trial: 6127885
Drug: Prenalterol infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prenalterol infusion (5 micrograms/kg/min for 30 min)
Trial: 6127885
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion (5 micrograms/kg/min for 30 min)
Trial: 6127885
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (5 micrograms/kg/min for 30 min)
Trial: 6127885
Drug: Prenalterol infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prenalterol infusion
Trial: 27993193
Drug: Bilberries (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilberries (150 g, 3 times a week for 6 weeks)
Trial: 27993193
Drug: Bilberries (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilberries (150 g, 3 times a week for 6 weeks) in men
Trial: 17601896
Drug: Ceftriaxone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone plus azithromycin (1 g per week for 2 weeks)
Trial: 17601896
Drug: Ceftriaxone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone plus doxycycline (200 mg/d for 2 weeks)
Trial: 9579500
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (4 microg/kg)
Trial: 9754085
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5-fluorouracil (5-FU) and 70% glycolic acid (GA)
Trial: 8151586
Drug: Bucillamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bucillamine (100 mg/day)
Trial: 1747791
Drug: 5-Fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil (5FU) administered as a protracted venous infusion
Trial: 30167975
Drug: Multiple exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple exercise therapy (training and stretching the knee and hip muscles)
Trial: 30167975
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (training the quadriceps muscles)
Trial: 17824884
Drug: Topical dry
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dry mouth products containing olive oil, betaine, and xylitol
Trial: 15922429
Drug: SWL plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SWL plus PDI therapy (median of four sessions, range 1 to 12)
Trial: 9040453
Drug: Nitrendipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10 to 40 mg/d) with possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12.5 to 25 mg/d)
Trial: 3227054
Drug: High-dose haloperidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose haloperidol (0.40 mg/kg)
Trial: 3227054
Drug: Low-dose haloperidol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose haloperidol (0.15 mg/kg)
Trial: 3227054
Drug: Test dose
RxNorm normalized name: Epinephrine/Lidocaine Hydrochloride Epidural Kit [ANESTHESIA TRAY (W/TEST DOSE)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test dose haloperidol (0.05 mg/kg)
Trial: 16225528
Drug: Darifenacin 7.5
RxNorm normalized name: darifenacin 7.5 MG
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Darifenacin 7.5 mg once daily
Trial: 16225528
Drug: Darifenacin 15
RxNorm normalized name: darifenacin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin 15 mg once daily
Trial: 16198072
Drug: Estradiol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (2 mg) and Norethisterone acetate (1 mg) daily for 6 months
Trial: 2005294
Drug: Out-patient clinic
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-patient clinic treatment
Trial: 29787859
Drug: Synbiotic (prebiotic:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic (prebiotic: fructooligosaccharides 4 g/day; probiotic: Bifidobacterium animalis subsp. lactis BB-12 at a minimum of 10 billion CFU/day)
Trial: 25684233
Drug: Vanoxerine 200
RxNorm normalized name: Vanoxerine
DrugBank: Vanoxerine (DB03701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vanoxerine 200 mg
Trial: 25684233
Drug: Vanoxerine 300
RxNorm normalized name: Vanoxerine
DrugBank: Vanoxerine (DB03701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vanoxerine 300 mg
Trial: 19038680
Drug: CRT-ON (Cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-ON (Cardiac Resynchronization Therapy)
Trial: 506742
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg imipramine
Trial: 506742
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg chlorimipramine
Trial: 25886483
Drug: Mock transcutaneous
RxNorm normalized name: mockernut extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock transcutaneous electrical nerve stimulation and sham intradermal acupuncture
Trial: 19700936
Drug: Tulobuterol patch
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol patch (TP) at 2mg/day plus ICS
Trial: 17760494
Drug: Morphine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (intravenous injection)
Trial: 17760494
Drug: Codeine (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (intramuscular route)
Trial: 11251433
Drug: Propofol target-concentration
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target-concentration infusion (4 mg.l‐1)
Trial: 11251433
Drug: 8% sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% sevoflurane inhalation with 50% nitrous oxide
Trial: 9758026
Drug: Continuous lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous lateral rotational therapy (CLRT) <40 degrees
Trial: 8993096
Drug: Glycine (0.4-0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine (0.4-0.8 g/kg/day) added to neuroleptics
Trial: 23683608
Drug: Acetazolamide (ACTZ)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACTZ) 500 mg administered intravenously to healthy subjects (HV)
Trial: 23683608
Drug: Acetazolamide (ACTZ)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACTZ) 500 mg administered intravenously to peritoneal dialysis patients (CAPD)
Trial: 16618980
Drug: nateglinide (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nateglinide (270 mg/day)
Trial: 16618980
Drug: voglibose (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: voglibose (0.6 mg/day)
Trial: 1683365
Drug: High-flow face
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow face mask oxygen therapy (control)
Trial: 7054205
Drug: 1.2 grams
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 grams of aspirin (low dose)
Trial: 7054205
Drug: 3.6 grams
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 grams of aspirin (high dose)
Trial: 22336473
Drug: Aspirin (100mg/day)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (100mg/day)
Trial: 22718810
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg/day + Azelnidipine 16 mg/day
Trial: 22718810
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg/day + Amlodipine 5 mg/day
Trial: 8302071
Drug: 50 ml/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml/min
Trial: 8302071
Drug: 75 ml/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 ml/min
Trial: 8302071
Drug: 100 ml/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml/min
Trial: 8302071
Drug: 200 ml/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml/min
Trial: 8302071
Drug: 300 ml/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml/min
Trial: 8302071
Drug: 500 ml/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml/min
Trial: 8302071
Drug: Low flow
RxNorm normalized name: high mallow flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flow groups (50, 75, 100 ml/min)
Trial: 8302071
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow groups (200, 300 ml/min)
Trial: 3291548
Drug: Pressure reducing
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pressure reducing medical therapy
Trial: 31774464
Drug: Ipilimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (10 mg/kg)
Trial: 31774464
Drug: Ipilimumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3 mg/kg or 10 mg/kg)
Trial: 28143504
Drug: Usual Treatment
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Treatment group (same information and counseling with limited interaction with the therapist)
Trial: 18617536
Drug: Gastrectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrectomy plus chemotherapy
Trial: 10689150
Drug: Intra-nasal live
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-nasal live attenuated influenza vaccine (Livac)
Trial: 10689150
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza vaccine (Ivac)
Trial: 10689150
Drug: Baculovirus recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baculovirus recombinant vaccine or adjuvanted Ivac
Trial: 9337824
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no long-term oxygen therapy)
Trial: 2880596
Drug: Etintidine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etintidine 300 mg b.d.
Trial: 2880596
Drug: Etintidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etintidine 400 mg b.d.
Trial: 2880596
Drug: Etintidine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etintidine 300 mg nocte.
Trial: 2880596
Drug: Etintidine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etintidine 600 mg nocte.
Trial: 2880596
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg nocte.
Trial: 2880596
Drug: Etintidine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etintidine 300 mg b.d. and 400 mg b.d.
Trial: 2880596
Drug: Etintidine (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etintidine (any dose) at bedtime.
Trial: 17388755
Drug: Biphasic inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biphasic inhalation profiles with low flow segments of 300 mL to 900 mL inhaled volume at 8 L/min
Trial: 17388755
Drug: Biphasic inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biphasic inhalation profiles
Trial: 12042887
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment for 12 months
Trial: 9527357
Drug: Chlorhexidine/thymol-containing varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine/thymol-containing varnish (Cervitec) applied twice within 3 days
Trial: 2378441
Drug: Terbutaline (Bricanyl)
RxNorm normalized name: terbutaline sulfate Oral Solution [Bricanyl]
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline (Bricanyl) 0.5 mg t.i.d. via Turbuhaler
Trial: 2378441
Drug: Fenoterol (Berotec)
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (Berotec) 0.2 mg t.i.d. via Inhalator Ingelheim
Trial: 1092727
Drug: Aspirin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3.6 Gm/day)
Trial: 17938939
Drug: Cholestyramine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine with biofeedback therapy (group A)
Trial: 17938939
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy alone (group B)
Trial: 12620169
Drug: 1.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% lidocaine and 0.3% nifedipine applied twice daily for 6 weeks
Trial: 8626984
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with Dermatophagoides extract
Trial: 1370507
Drug: Detirelix 1
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Detirelix 1 mg
Trial: 1370507
Drug: Detirelix 5
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Detirelix 5 mg
Trial: 1370507
Drug: Detirelix 20
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Detirelix 20 mg
Trial: 1370507
Drug: Detirelix 5
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Detirelix 5 mg and 20 mg
Trial: 3383879
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (20 mg)
Trial: 24281893
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Caffeine and Sodium Citrate
Trial: 20702609
Drug: 75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 μg I/d supplementation
Trial: 20702609
Drug: 150 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 μg I/d supplementation
Trial: 16583464
Drug: LD-rofecoxib (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD-rofecoxib (0.3 mg/kg/day up to 12.5 mg/day)
Trial: 16583464
Drug: HD-rofecoxib (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD-rofecoxib (0.6 mg/kg/day up to 25 mg/day)
Trial: 16583464
Drug: naproxen (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen (15 mg/kg/day)
Trial: 12664078
Drug: GLP‐2 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP‐2 infusion (25 pmol/kg body weight) for 4.5 hours
Trial: 9169336
Drug: UVB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB plus calcipotriene 0.005% ointment twice daily
Trial: 3886302
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg mecillinam daily for 14 days
Trial: 30554092
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids and vitamin E co-supplementation (1000 mg/day of omega-3 from flaxseed oil plus 400 IU/day of vitamin E)
Trial: 29800375
Drug: Ketamine (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1-2 mg/kg IV bolus, then continuous infusion starting at 5 mcg/kg/min, titrated as needed)
Trial: 22345630
Drug: Multimodal behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal behavioral treatment (MBT)
Trial: 19929593
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch with concomitant memantine
Trial: 19929593
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch without concomitant memantine
Trial: 16263779
Drug: Intramuscular corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular corticosteroid injections (40 mg methylprednisolone acetate)
Trial: 12883695
Drug: Fixed dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosing of epoetin alpha (10,000 IU)